TP53 and prostate cancer: Patients with a molecular signature of aggressive variant prostate cancer (AVPC, n = 12), comprised of loss-of-function alterations in at least two of the three genes: TP53, RB1, PTEN, had a shorter PFS on PSMA-RLT (HR 1.8; 95%CI 1.0 - 3.4; Supplementary Figure 1).